WNT3A and colorectal carcinoma: Consistent with these data, RT-qPCR screening assays performed on Wnt target genes showed that their high mRNA expression levels detected after activation of the Wnt pathway (Wnt3a and TWS-119) decreased significantly upon p38α pharmacological inhibition with ralimetinib or genetic ablation with a specific siRNA (Fig. 5B), indicating that p38α inhibition or genetic ablation reduces β-catenin transcriptional activity in HT-29 CRC cells.